The emergence of the cicada COVID variant, scientifically named BA.3.2, has raised alarm bells across the United States as it spreads rapidly, detected in at least 25 states as of February 2026. This heavily mutated strain of SARS-CoV-2 is believed to have the potential to evade immunity gained from vaccinations or previous infections, making it a significant public health concern.
First identified in South Africa in November 2024, BA.3.2 has since made its way to at least 23 countries, with a notable presence in Denmark, Germany, and the Netherlands, where it accounts for approximately 30% of cases. The variant is characterized by an astonishing 70 to 75 mutations in its spike protein, which may compromise the effectiveness of existing vaccines against infection, although they are still expected to provide protection against severe disease.
Dr. Andrew Pekosz, a prominent virologist, emphasized the variant’s unique mutation profile, stating, “It has a lot of mutations that may cause it to look different to your immune system.” This characteristic is particularly concerning as it could lead to a resurgence of COVID-19 cases, despite the ongoing vaccination efforts.
Despite these alarming features, health experts, including Dr. Adolfo García-Sastre, have noted that there is currently no evidence to suggest that BA.3.2 is causing more severe disease or higher hospitalization rates compared to previous strains. Symptoms associated with this variant include cough, fever, sore throat, and gastrointestinal issues, which are consistent with common COVID-19 symptoms.
The World Health Organization has classified BA.3.2 as a ‘variant under monitoring’ since December 2025, highlighting the need for continued surveillance and research. As of now, approximately 3.7% of sewage samples nationwide have shown traces of BA.3.2, indicating its presence in the community.
While the variant’s unusual emergence pattern has drawn comparisons to the lifecycle of a cicada, the reasons behind its resurgence remain unclear. Public health officials are closely monitoring the situation, as the long-term impact of BA.3.2 on public health is still uncertain.
As the situation evolves, vaccination continues to be a critical tool in limiting the spread of BA.3.2. Dr. Pekosz reassured the public, stating, “Vaccination is still going to help limit cases.” However, the effectiveness of current vaccines against this variant is a growing concern.
With BA.3.2 continuing to spread, health authorities urge the public to remain vigilant and adhere to safety measures. Details remain unconfirmed regarding the variant’s full implications, but the potential for increased cases underscores the importance of ongoing research and public health initiatives.
